DOCSLIB.ORG

Optimization of Expression Conditions Enhances Production Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Optimization of Expression Conditions Enhances Production Of J. Microbiol. Biotechnol. (2015), 25(10), 1709–1713 http://dx.doi.org/10.4014/jmb.1506.06034 Research Article Review jmb Optimization of Expression Conditions Enhances Production of Sepiapterin, a Precursor for Tetrahydrobiopterin Biosynthesis, in Recombinant Escherichia coli Eun-Hee Park1, Won-Heong Lee2, Mi-Hee Jang1, and Myoung-Dong Kim1* 1Department of Food Science and Biotechnology, Kangwon National University, Chuncheon 200-701, Republic of Korea 2Department of Bioenergy Science and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea Received: June 15, 2015 Revised: July 16, 2015 Sepiapterin is a precursor for the synthesis of tetrahydrobiopterin (BH4), which is a well- Accepted: July 18, 2015 known cofactor for aromatic amino acid hydroxylation and nitric oxide synthesis in higher mammals. In this study, a recombinant Escherichia coli BL21(DE3) strain harboring cyanobacterial guanosine 5’-triphosphate cyclohydrolase 1 (GCH1) and human 6- First published online pyruvoyltetrahydropterin synthase (PTPS) genes was constructed to produce sepiapterin. The July 22, 2015 optimum conditions for T7 promoter–driven expression of GCH1 and PTPS were 30°C and *Corresponding author 0.1 mM isopropyl-β-D-thioglucopyranoside (IPTG). The maximum sepiapterin concentration Phone: +82-33-250-6458; of 88.1 ± 2.4 mg/l was obtained in a batch cultivation of the recombinant E. coli, corresponding Fax: +82-33-259-5565; to an 18-fold increase in sepiapterin production compared with the control condition (37°C E-mail: [email protected] and 1 mM IPTG). pISSN 1017-7825, eISSN 1738-8872 Copyright© 2015 by Keywords: Sepiapterin, GTP cyclohydrolase 1 (GCH1), 6-pyruvoyltetrahydropterin synthase The Korean Society for Microbiology (PTPS), Escherichia coli and Biotechnology Tetrahydrobiopterin (BH4) is a well-known essential ovarian cancer cells. cofactor for phenylalanine hydroxylase [5], tyrosine The BH4 biosynthetic pathway begins from GTP as a hydroxylase [11], tryptophan hydroxylase [8], fatty acid starting material in the de novo pathway (Fig. 1). In the first glycerylether oxygenase [18], and nitric oxide synthase [6]. reaction, GTP is converted to dihydroneopterin triphosphate Decreased levels of BH4 in the cerebrospinal fluid have (NH2TP) by GTP-cyclohydrolase 1 (GCH1) (E.C. 3.5.4.16) been documented in neurological diseases presenting [12], and then NH2TP is converted to 6-pyruvoyl- phenotypically without hyperphenylalaninemia, such as tetrahydropterin (6PPH4) by 6-pyruvoyltetrahydropterin Parkinson’s disease [3, 19], autism [4], depression [20], and synthase (PTPS) (E.C. 4.2.3.12). Finally, BH4 is produced Alzheimer’s disease [1]. Sepiapterin can be used as a through a reaction catalyzed by sepiapterin reductase (SR) precursor of the salvage pathway for BH4 synthesis as well (E.C. 1.1.1.153) [19]. Alternatively, aldose reductase (E.C. as a substitute to BH4. When sepiapterin is added to 1.1.1.21) catalyzes the reduction of the C-2’ oxo group in mammalian tissue culture instead of BH4, it can show the PPH4, yielding 6-lactoyltetrahydropterin (LPH4) [10], same effect as BH4 [16]. Sepiapterin is more stable than BH4 which is further reduced to BH4 by SR or is converted and its synthesis is not affected by the cellular BH4 level, nonenzymatically to its dihydro form, sepiapterin. Escherichia which suggests that sepiapterin can replace BH4 when the coli is unable to produce either BH4 or sepiapterin because latter is absent [15]. Sepiapterin administration can prevent it lacks BH4 biosynthetic enzymes; however, in this renal damage in a rat model of acute kidney injury after study we demonstrate that simple introduction of two suprarenal aortic clamping [7] and reduces postischemic heterologous biosynthetic enzymes and optimization of the injury in the rat heart [17]. Cho et al. [2] reported that culture conditions can lead to the formation of considerable sepiapterin inhibits the proliferation and migration of amounts of sepiapterin in E. coli. October 2015 ⎪ Vol. 25⎪ No. 10 1710 Park et al. methods described by Sambrook and Russell [13]. To determine the optimal expression conditions for the GCH1 and PTPS genes, various sets of the induction temperature and concentration of isopropyl-β-D- thiogalactopyranoside (IPTG) were tested. E. coli BL21(DE3) cells harboring pME721 were grown in semi-synthetic medium (100 ml) at 37°C until the dry cell mass reached 0.3 g/l. IPTG was then added to induce T7 promoter– driven expression of both genes. To verify the expression of the GCH1 and PTPS genes, cells induced for 4 h were harvested by centrifugation at 10,000 ×g for 5 min at 4°C, resuspended in lysis buffer [13], and disrupted using an ultrasonic processor (Cole-Parmer, Vernon Hills, IL, USA). Crude extracts were fractionated into soluble and insoluble fractions by centrifugation at 16,000 ×g for 10 min at 4°C. Fig. 1. The sepiapterin biosynthetic pathway from glycerol. Soluble and insoluble protein fractions were analyzed by GAP, glyceraldehyde 3’-phosphate; IMP, inosine 5’-monophosphate; XMP, xanthosine 5’-monophospate; GMP, guanosine 5’-monophosphate; sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE; 10% polyacrylamide). Gels were stained with GDP, guanosine 5’-diphosphate; GTP, guanosine 5’-triphosphate; NH2TP, Coomassie Brilliant Blue R-250. The dry cell mass 7,8-dihydroneopterin; 6PPH4, 6-pyruvoyltetrahydropterin; LPH4, 6- lactoyltetrahydropterin; 1’-oxo-TP, 1’-oxo-2’-hydroxypropyltetrahydropterin. concentration was determined from the optical density of the culture broth measured at 600 nm and a predetermined standard curve. To determine sepiapterin concentrations, Escherichia coli TOP10 and BL21(DE3) strains (Invitrogen, filtered (0.2 µm) culture broth and crude cell extract were Carlsbad, CA, USA) were used as hosts for genetic injected into an Inertsil ODS-3 column (GL Sciences Inc., manipulation and sepiapterin production, respectively. Tokyo, Japan) installed on the HPLC system and Plasmid pETDuet-1 (pBR322 replicon, Ampr) was purchased equilibrated at 40°C with 10 mM sodium phosphate (pH from Merck Biosciences (Darmstadt, Germany) and used to 6.0). The column was eluted with the same buffer at a flow express GCH1 and PTPS. Luria-Bertani (LB) medium [9] rate of 1.2 ml/min. Detection was performed using a UV/ and a semi-synthetic medium [14] supplemented with Visible detector (Shimadzu, Japan). LC-MS/MS analyses glycerol (2% (w/v)) as a carbon source were used for were performed on a Thermo Scientific TSQ Quantum plasmid DNA preparation and sepiapterin production, Ultra triple quadrupole mass spectrometer (Thermo Electron respectively. Ampicillin (Sigma-Aldrich, St. Louis, MO, Corp., WI, USA) in the positive electrospray ionization USA) was added at a final concentration of 50 mg/l to mode with the following operation parameters: capillary select plasmid-harboring E. coli cells. Cyanobacterial GCH1 voltage, 3.6 kV; ion source, 5.5 kV; temperature, 320°C; (GenBank Accession No. AY120852.1; 0.7 kb) and human mobile phase, 10% methanol; and flow rate, 200 µl/min. PTPS (GenBank Accession No. NM_000317.2; 0.4 kb) genes Commercial human sepiapterin (Sigma-Aldrich) was used were synthesized by Bioneer (Daejeon, Korea). The primers as a standard for analysis. All experiments were performed used for PCR were GCH1-F (5’-AATT CCATGGTGT in triplicate. TGAGGTTTCTTGTGACGAT-3’), GCH1-R (5’-AATTCT To examine the effects of IPTG concentration and GCAGTTAGGCAAATGCGGCAGGTT-3’), PTPS-F (5’- induction temperature on the expression of GCH1 and AATTCATATGAGCACGGAAGGTGGTGG-3’), and PTPS- PTPS, recombinant E. coli BL21(DE3) cultures were induced R (5’-AATTCTCGAGCTATTCTCCTTTATAAACCA-3’); with various concentrations of IPTG and incubated at 25°C, plasmids pGEMT-GCH1 (pME752) and pGEMT-PTPS 30°C, or 37°C. As shown in Fig. 2, SDS-PAGE analysis of (pME935) was used as respective templates. The amplified recombinant E. coli extracts indicated that GCH1 was mostly products were digested with NcoI/PstI and NdeI/XhoI, expressed as insoluble inclusion bodies. The induction respectively, and cloned into pETDuet-1. The resulting temperature of 30°C was optimal based on the total plasmid, pME721 (6.6 kb), was sequenced using vector- amount of GCH1 produced. When IPTG was added at a and insert-specific primers. All DNA manipulations and final concentration of 0.1 mM, the fraction of soluble GCH1 bacterial transformations were performed according to the was higher than with other IPTG concentrations; the total J. Microbiol. Biotechnol. Sepiapterin Production in Recombinant Escherichia coli 1711 Fig. 2. SDS-PAGE analysis of GCH1 and PTPS expression in Electrospray ionization mass spectra of the sepiapterin recombinant E. coli BL21(DE3). Fig. 3. standard (A) and cell-free culture broth (B), and HPLC Cells were harvested after 4-h induction with IPTG at 25°C (A), 30°C (B), or 37°C (C). T, S, and I denote total, soluble, and insoluble protein analysis of cell-free culture broth (C). fractions, respectively. Arrows indicate protein bands that match the Cell-free culture broth of recombinant E. coli BL21(DE3) was obtained estimated molecular mass of GCH1 and PTPS. Lane M, molecular after 4-h induction by 0.1 mM IPTG at 30°C. weight marker. The gel was stained with Coomassie Brilliant Blue R-250. the recombinant E. coli BL21(DE3) strain harboring plasmid pME721. Electrospray ionization-MS spectra of both the GCH1 level was similar at all tested IPTG concentrations. sepiapterin standard (Fig. 3A) and culture broth of However, no noticeable amount of soluble PTPS was recombinant E. coli (Fig. 3B) showed a compound with m/z detected under any induction conditions, indicating that 234.02. HPLC analysis revealed that a compound with a further studies are needed to increase the expression level retention time identical to that of the sepiapterin standard of cyanobacterial PTPS or to clone other PTPS genes was produced in recombinant E. coli BL21(DE3)/pME721 that may encode more soluble proteins. The maximum (Fig. 3C). Sepiapterin was not produced in the control sepiapterin concentration of 88.1 ± 2.4 mg/l was obtained strain harboring the empty vector (pETDuet-1).
Load more

Recommended publications
  • Diosynrhesis of Neopterin, Sepioprerin, Ond Diopterin in Rar Ond Humon Oculor Tissues
    768 INVESTIGATIVE OPHTHALMOLOGY b VISUAL SCIENCE / May 1985 Vol. 26 before and after the addition of beta-glucuronidase.4 ported by the Juvenile Diabetes Foundation and by the University In circumstances where the actual plasma free fluo- of London, Central Research Fund. The HPLC was purchased with an MRC grant to Dr. Michael J. Neal. Submitted for publi- rescein has not been measured, the term "plasma- cation: April 12, 1984. Reprint requests: Dr. P. S. Chahal, Depart- free fluorescence" should be quoted. It is then better ment of Medicine, Hammersmith Hospital, Du Cane Road, London to measure overall fluorescence (fluorescein and the W12 OHS, England. glucuronide metabolite) in protein-free plasma ultra- filtrate and the fluorescence appearing in the ocular References compartments using the same excitor and emission filters. 1. Araie M, Sawa M, Nagataki S, and Mishima S: Aqueous Fluorescein glucuronide is a potential source of humor dynamics in man as studied by oral fluorescein. Jpn J Ophthalmol 24:346, 1980. variability in studies of blood-ocular dynamics using 2. Zeimer RC, Blair NP, and Cunha-Vaz JG: Pharmacokinetic fluorescein. Its exact role has yet to be established. interpretation of vitreous fluorophotometry. Invest Ophthalmol VisSci 24:1374, 1983. Key words: Blood-ocular barriers, diabetes, plasma ultrafil- 3. Chen SC, Nakamura H, and Tamura Z: Studies on metabolite trate, fluorescein glucuronide, fluorescence, protein-binding of fluorescein in rabbit and human urine. Chem Pharmacol Acknowledgments. Technical assistance was given by Dr. Bull 28:1403, 1980. J. Cunningham, Ian Joy, and Margaret Foster. 4. Chen SC, Nakamura H, and Tamura Z: Determination of fluorescein and fluorescein monoglucuronide excreted in urine.
    [Show full text]
  • Isolation and Expression of Rat Liver Sepiapterin Reductase Cdna
    Proc. Nat!. Acad. Sci. USA Vol. 87, pp. 6436-6440, August 1990 Genetics Isolation and expression of rat liver sepiapterin reductase cDNA (tetrahydrobiopterin/biopterin/pyruvoyltetrahydropterin/aromatic amino acid hydroxylase/molecular cloning) BRUCE A. CITRON*, SHELDON MILSTIEN*, JOANNE C. GUTIERREZt, ROBERT A. LEVINE, BRENDA L. YANAK*§, AND SEYMOUR KAUFMAN*¶ *Laboratory of Neurochemistry, Room 3D30, Building 36, and tLaboratory of Cell Biology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892; and tLaboratory of Molecular Neurobiology, Lafayette Clinic, 951 East Lafayette, Detroit, MI 48207 Contributed by Seymour Kaufman, June 7, 1990 ABSTRACT Sepiapterin reductase (7,8-dihydrobiopterin: either case, the final carbonyl reduction to form tetrahydro- NADP+ oxidoreductase, EC 1.1.1.153) catalyzes the terminal biopterin must be catalyzed by sepiapterin reductase. step in the biosynthetic pathway for tetrahydrobiopterin, the In the present study, we have screened a rat liver cDNA cofactor necessary for aromatic amino acid hydroxylation. We library with a specific antibody that reacts positively to the report here the isolation of a cDNA clone for rat liver sepia- enzyme band on Western blots (19). These clones were used pterin reductase. The cDNA has been excised from a lambda to further characterize the enzyme and to begin to elucidate vector and the DNA sequence was determined. The insert the functional sites ofthe enzymes in the tetrahydrobiopterin contains the coding sequence for at least 95% of the rat enzyme biosynthetic pathway. 11 and is fused to the Escherichia coli (3-galactosidase N-terminal segment and the lac promoter. The N-terminal region of the clone contains an extraordinarily high G+C content.
    [Show full text]
  • Epithelial Cell Line Derived from Endometriotic Lesion Mimics Macrophage Nervous Mechanism of Pain Generation on Proteome and Metabolome Levels
    biomolecules Article Epithelial Cell Line Derived from Endometriotic Lesion Mimics Macrophage Nervous Mechanism of Pain Generation on Proteome and Metabolome Levels Benjamin Neuditschko 1,2,† , Marlene Leibetseder 1,† , Julia Brunmair 1 , Gerhard Hagn 1 , Lukas Skos 1, Marlene C. Gerner 3 , Samuel M. Meier-Menches 1,2,4 , Iveta Yotova 5 and Christopher Gerner 1,4,* 1 Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 38, 1090 Vienna, Austria; [email protected] (B.N.); [email protected] (M.L.); [email protected] (J.B.); [email protected] (G.H.); [email protected] (L.S.); [email protected] (S.M.M.-M.) 2 Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Straße 42, 1090 Vienna, Austria 3 Division of Biomedical Science, University of Applied Sciences, FH Campus Wien, Favoritenstraße 226, 1100 Vienna, Austria; [email protected] 4 Joint Metabolome Facility, Faculty of Chemistry, University of Vienna, Waehringer Straße 38, 1090 Vienna, Austria 5 Department of Obstetrics and Gynaecology, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria; [email protected] Citation: Neuditschko, B.; * Correspondence: [email protected] Leibetseder, M.; Brunmair, J.; Hagn, † Authors contributed equally. G.; Skos, L.; Gerner, M.C.; Meier-Menches, S.M.; Yotova, I.; Abstract: Endometriosis is a benign disease affecting one in ten women of reproductive age world- Gerner, C. Epithelial Cell Line wide. Although the pain level is not correlated to the extent of the disease, it is still one of the Derived from Endometriotic Lesion cardinal symptoms strongly affecting the patients’ quality of life.
    [Show full text]
  • Treatable Inborn Errors of Metabolism Presenting As Cerebral Palsy Mimics
    Leach et al. Orphanet Journal of Rare Diseases 2014, 9:197 http://www.ojrd.com/content/9/1/197 RESEARCH Open Access Treatable inborn errors of metabolism presenting as cerebral palsy mimics: systematic literature review Emma L Leach1,2, Michael Shevell3,4,KristinBowden2, Sylvia Stockler-Ipsiroglu2,5,6 and Clara DM van Karnebeek2,5,6,7,8* Abstract Background: Inborn errors of metabolism (IEMs) have been anecdotally reported in the literature as presenting with features of cerebral palsy (CP) or misdiagnosed as ‘atypical CP’. A significant proportion is amenable to treatment either directly targeting the underlying pathophysiology (often with improvement of symptoms) or with the potential to halt disease progression and prevent/minimize further damage. Methods: We performed a systematic literature review to identify all reports of IEMs presenting with CP-like symptoms before 5 years of age, and selected those for which evidence for effective treatment exists. Results: We identified 54 treatable IEMs reported to mimic CP, belonging to 13 different biochemical categories. A further 13 treatable IEMs were included, which can present with CP-like symptoms according to expert opinion, but for which no reports in the literature were identified. For 26 of these IEMs, a treatment is available that targets the primary underlying pathophysiology (e.g. neurotransmitter supplements), and for the remainder (n = 41) treatment exerts stabilizing/preventative effects (e.g. emergency regimen). The total number of treatments is 50, and evidence varies for the various treatments from Level 1b, c (n = 2); Level 2a, b, c (n = 16); Level 4 (n = 35); to Level 4–5 (n = 6); Level 5 (n = 8).
    [Show full text]
  • Inherited Disorders of Neurotransmitters: Classification and Practical Approaches for Diagnosis and Treatment
    Published online: 2018-10-29 2 Review Article Inherited Disorders of Neurotransmitters: Classification and Practical Approaches for Diagnosis and Treatment Heiko Brennenstuhl1 Sabine Jung-Klawitter1 Birgit Assmann1 Thomas Opladen1 1 Division of Neuropediatrics and Metabolic Medicine, Department of Address for correspondence Prof. Dr. Thomas Opladen, MD, Division General Pediatrics, University Children’s Hospital Heidelberg, of Neuropediatrics and Metabolic Medicine, Department of General Heidelberg, Germany Pediatrics, Im Neuenheimer Feld 430, D-69120 Heidelberg, Germany (e-mail: [email protected]). Neuropediatrics 2019;50:2–14. Abstract Neurotransmitter deficiencies are rare neurological disorders with clinical onset during childhood. The disorders are caused by genetic defects in the enzymes involved in synthesis, degradation, or transport of neurotransmitters or by defects in the cofactor biosynthesis such as tetrahydrobiopterin (BH4). With the newly described DNAJC12 deficiency, a chaperon-associated neurotransmitter disorder, the pathophysiological spectrum has been broadened. All deficiencies result in a lack of monoamine neurotransmitters, especially dopamine and its products, with a subset leading to decreased levels of serotonin. Symptoms can occur already in the neonatal period. Keywords Classical signs are hypotonia, movement disorders, autonomous dysregulations, and ► inherited monoamine impaired development. Diagnosis depends on quantitative detection of neurotrans- neurotransmitter mitters in cerebrospinal
    [Show full text]
  • Pharmacological Assessment of Sepiapterin Reductase Inhibition on Tactile Response in the Rat
    JPET Fast Forward. Published on May 20, 2019 as DOI: 10.1124/jpet.119.257105 This article has not been copyedited and formatted. The final version may differ from this version. JPET 257105 Manuscript title Pharmacological assessment of sepiapterin reductase inhibition on tactile response in the rat Authors and affiliations James T. Meyer, Brian A. Sparling, William J. McCarty, Maosheng Zhang, Marcus Soto, Stephen Schneider, Hao Chen, Jonathan Roberts, Helming Tan, Thomas Kornecook, Paul Andrews, Charles G. Knutson. Downloaded from Amgen Research, One Amgen Center Drive, Thousand Oaks, CA 91320, United States (JTM, MZ, MS, HT, TK) jpet.aspetjournals.org Amgen Research, 360 Binney Street, Cambridge, MA 02142, United States. (BAS, WJM, SS, HC, JR, PA, CGK) at ASPET Journals on September 26, 2021 Public Information 1 JPET Fast Forward. Published on May 20, 2019 as DOI: 10.1124/jpet.119.257105 This article has not been copyedited and formatted. The final version may differ from this version. JPET 257105 Running Title: PK/PD relationship with sepiapterin reductase inhibition Corresponding Author: Charles G. Knutson Amgen Research Department of Pharmacokinetics and Drug Metabolism Downloaded from Amgen Inc. 360 Binney Street jpet.aspetjournals.org AMA1/4-G-10 Cambridge, MA 02142 at ASPET Journals on September 26, 2021 Tel. 617.444.5470 E-mail: [email protected] Numbers: Text pages: 34 Number of tables: 3 Number of figures: 4 Number of references: 27 Number of words in Abstract: 241 Number of words in Introduction: 652 Number of words in Discussion: 1262 Public Information 2 JPET Fast Forward. Published on May 20, 2019 as DOI: 10.1124/jpet.119.257105 This article has not been copyedited and formatted.
    [Show full text]
  • Analysis of Catecholamines and Pterins in Inborn Errors of Monoamine Neurotransmitter Metabolism—From Past to Future
    cells Review Analysis of Catecholamines and Pterins in Inborn Errors of Monoamine Neurotransmitter Metabolism—From Past to Future Sabine Jung-Klawitter * and Oya Kuseyri Hübschmann Department of General Pediatrics, Division of Neuropediatrics and Metabolic Medicine, University Hospital Heidelberg, 69120 Heidelberg, Germany * Correspondence: [email protected]; Tel.: +49-(0)6221-5639586 Received: 30 June 2019; Accepted: 4 August 2019; Published: 9 August 2019 Abstract: Inborn errors of monoamine neurotransmitter biosynthesis and degradation belong to the rare inborn errors of metabolism. They are caused by monogenic variants in the genes encoding the proteins involved in (1) neurotransmitter biosynthesis (like tyrosine hydroxylase (TH) and aromatic amino acid decarboxylase (AADC)), (2) in tetrahydrobiopterin (BH4) cofactor biosynthesis (GTP cyclohydrolase 1 (GTPCH), 6-pyruvoyl-tetrahydropterin synthase (PTPS), sepiapterin reductase (SPR)) and recycling (pterin-4a-carbinolamine dehydratase (PCD), dihydropteridine reductase (DHPR)), or (3) in co-chaperones (DNAJC12). Clinically, they present early during childhood with a lack of monoamine neurotransmitters, especially dopamine and its products norepinephrine and epinephrine. Classical symptoms include autonomous dysregulations, hypotonia, movement disorders, and developmental delay. Therapy is predominantly based on supplementation of missing cofactors or neurotransmitter precursors. However, diagnosis is difficult and is predominantly based on quantitative detection of neurotransmitters, cofactors, and precursors in cerebrospinal fluid (CSF), urine, and blood. This review aims at summarizing the diverse analytical tools routinely used for diagnosis to determine quantitatively the amounts of neurotransmitters and cofactors in the different types of samples used to identify patients suffering from these rare diseases. Keywords: inborn errors of metabolism; catecholamines; pterins; HPLC; fluorescence detection; electrochemical detection; MS/MS 1.
    [Show full text]
  • Consensus Guideline for the Diagnosis and Treatment of Tetrahydrobiopterin
    Opladen et al. Orphanet Journal of Rare Diseases (2020) 15:126 https://doi.org/10.1186/s13023-020-01379-8 REVIEW Open Access Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies Thomas Opladen1*†, Eduardo López-Laso2†, Elisenda Cortès-Saladelafont3,4†, Toni S. Pearson5, H. Serap Sivri6, Yilmaz Yildiz6, Birgit Assmann1, Manju A. Kurian7,8, Vincenzo Leuzzi9, Simon Heales10, Simon Pope10, Francesco Porta11, Angeles García-Cazorla3, Tomáš Honzík12, Roser Pons13, Luc Regal14, Helly Goez15, Rafael Artuch16, Georg F. Hoffmann1, Gabriella Horvath17, Beat Thöny18, Sabine Scholl-Bürgi19, Alberto Burlina20, Marcel M. Verbeek21, Mario Mastrangelo9, Jennifer Friedman22, Tessa Wassenberg14, Kathrin Jeltsch1†, Jan Kulhánek12*†, Oya Kuseyri Hübschmann1† and on behalf of the International Working Group on Neurotransmitter related Disorders (iNTD) Abstract Background: Tetrahydrobiopterin (BH4) deficiencies comprise a group of six rare neurometabolic disorders characterized by insufficient synthesis of the monoamine neurotransmitters dopamine and serotonin due to a disturbance of BH4 biosynthesis or recycling. Hyperphenylalaninemia (HPA) is the first diagnostic hallmark for most BH4 deficiencies, apart from autosomal dominant guanosine triphosphate cyclohydrolase I deficiency and sepiapterin reductase deficiency. Early supplementation of neurotransmitter precursors and where appropriate, treatment of HPA results in significant improvement of motor and cognitive function. Management approaches differ across the world
    [Show full text]
  • A Murine Model for Human Sepiapterin-Reductase Deficiency
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector A Murine Model for Human Sepiapterin-Reductase Deficiency Seungkyoung Yang,1,3,* Young Jae Lee,3,* Jin-Man Kim,2 Sean Park,3 Joanna Peris,5 Philip Laipis,4 Young Shik Park,6 Jae Hoon Chung,1 and S. Paul Oh3 1Department of Biological Sciences, Korea Advanced Institute of Science and Technology, and 2Department of Pathology, Chungnam National University School of Medicine, Daejeon, South Korea; Departments of 3Physiology and Functional Genomics and 4Biochemistry and Molecular Biology, University of Florida College of Medicine, and 5Department of Pharmacodynamics, University of Florida College of Pharmacy, Gainesville; and 6School of Biotechnology and Biomedical Science, Inje University, Kimhae, South Korea Tetrahydrobiopterin (BH4) is an essential cofactor for several enzymes, including all three forms of nitric oxide synthases, the three aromatic hydroxylases, and glyceryl-ether mono-oxygenase. A proper level of BH4 is, therefore, necessary for the metabolism of phenylalanine and the production of nitric oxide, catecholamines, and serotonin. BH4 deficiency has been shown to be closely associated with diverse neurological psychiatric disorders. Sepiapterin reductase (SPR) is an enzyme that catalyzes the final step of BH4 biosynthesis. Whereas the number of cases of neuropsychological disorders resulting from deficiencies of other catalytic enzymes involved in BH4 biosynthesis and metabolism has been increasing, only a handful of cases of SPR deficiency have been reported, and the role of SPR in BH4 biosynthesis in vivo has been poorly understood. Here, we report that mice deficient in the Spr gene (Spr5/5) display disturbed pterin profiles and greatly diminished levels of dopamine, norepinephrine, and serotonin, indicating that SPR is essential for homeostasis of BH4 and for the normal functions of BH4-dependent enzymes.
    [Show full text]
  • A Comparison of Sepiapterin and Tetrahydrobiopterin Uptake by BRL2H3 Cells
    Yamamoto et al.: Tetrahydrobiopterin uptake Pteridines Vol. 7, 1996, pp. 154~ 156 A Comparison of Sepiapterin and Tetrahydrobiopterin Uptake by BRL2H3 Cells 2 Kazumasa Yamamoto!, Mutsumi Nagano!, Nobuo Nakanishi , and Hiroyuki Hasegawa! § !Department of Bioscience, Teikyo University of Science, Uenohara, Yamanashi 409-01 2Department of Biochemistry, Meikai University School of Dentistry, Sakato, Saitama 350-02, Japan (Received October 4, 1996) Summary Cellular uptake of sepiapterin and tetrahydrobiopterin was compared quantitatively with RBL2H3 cells in culture. RBL2H3 is a mast cell line and has the ability to synthesize serotonin. Sepiapterin was in­ corporated and converted into tetrahydrobiopterin in the cell. The incorporation of sepiapterin was about 10 times faster than tetrahydrobiopterin. A low concentration of tetrahydrobiopterin was in­ corporated in a saturable manner up to about 10 J..LM, and it was superimposed upon a linearly con­ centration-dependent process. Overnight treatment with DAHP depleted endogenous tetrahy­ drobiopterin. The DAHP treated cells took up tetrahydrobiopterin faster than untreated cells. Introduction In this report, incorporation of sepiapterin and tetrahydrobiopterin was compared using RBL2H3 Tetrahydrobiopterin plays an essential role as cells in culture. The cells can synthesize. tetrahy­ cofactor of variety of hydroxylases or oxygen-linked drobiopterin and utilize it in its biosynthesis of enzymic reactions such as phenylalanine hydroxy­ serotonin as a cofactor of tryptophan hydroxylase. lase (1), tyrosine hydroxylase (2), tryptophan hy­ droxylase (3), glyceryl-ether mono-oxygenase (4), Materials and Methods and NO-synthetase (5). In case of newborn error in tetrahydrobiopterin metabolism which leads to Tetrahydrobiopterin was donated by Suntory Ltd. insufficient supply of this compound, tetrahydro­ (Tokyo, Japan), sepiapterin was purchased from biopterin therapy is unavoidable.
    [Show full text]
  • Tetrahydrobiopterin Biosynthesis As an Off-Target of Sulfa Drugs
    RCSB PDB-101 http://www.rcsb.org/pdb/101/motm.do?momID=188 | An Educational Resource for Exploring a Structural View of Biology Contact Us | Print Jump to a Molecule: Structural View of Biology >> Health and Disease >> Molecular Basis of Disease Structural View of Biology Browser Educational Resources Molecule of the Month Understanding PDB Data Author Profiles Video Challenge Curriculum August 2015 Molecule of the Month by David Goodsell doi: 10.2210/rcsb_pdb/mom_2015_8 (ePub Version ) Keywords: tetrahydrobiopterin, enzyme cofactor, hydroxylation, neurotransmitters, dopamine Introduction Enzymes that perform unusual chemical reactions often need some assistance. The twenty natural amino acids have many different chemical properties that may be used to catalyze chemical reactions, but sometimes amino acids just aren't enough. In these cases, cofactors with special chemical properties provide the necessary chemical expertise and enzymes use them as tiny tools to perform their reactions. For instance, tetrahydrobiopterin is a cofactor used by several enzymes that juggle molecular oxygen, attaching it to amino acids and other molecules. Building a Cofactor Three enzymes build tetrahydrobiopterin starting from GTP. The first step, which is the committing step for the whole process, is performed by a large enzyme complex called GTP cyclohydrolase I (GTPCH, shown here from PDB entry 1gtp ). It breaks the smaller ring in the guanine base, opens up the sugar, and reconnects everything to form a slightly larger ring. In the second step, the enzyme 6-pyruvoyl-tetrahydropterin synthase (PTPS, PDB entry 1gtq ) swaps a few atoms around in the ring and clips off the phosphates. Finally, the enzyme sepiapterin reductase (SR, PDB entry 1sep ) cleans up the portion of the sugar that is left to form the final cofactor.
    [Show full text]
  • Sepiapterin Reductase Deficiency
    Sepiapterin reductase deficiency Description Sepiapterin reductase deficiency is a condition characterized by movement problems, most often a pattern of involuntary, sustained muscle contractions known as dystonia. Other movement problems can include muscle stiffness (spasticity), tremors, problems with coordination and balance (ataxia), and involuntary jerking movements (chorea). People with sepiapterin reductase deficiency can experience episodes called oculogyric crises. These episodes involve abnormal rotation of the eyeballs; extreme irritability and agitation; and pain, muscle spasms, and uncontrolled movements, especially of the head and neck. Movement abnormalities are often worse late in the day. Most affected individuals have delayed development of motor skills such as sitting and crawling, and they typically are not able to walk unassisted. The problems with movement tend to worsen over time. People with sepiapterin reductase deficiency may have additional signs and symptoms including an unusually small head size (microcephaly), intellectual disability, seizures, excessive sleeping, and mood swings. Frequency Sepiapterin reductase deficiency appears to be a rare condition. At least 30 cases have been described in the scientific literature. Causes Mutations in the SPR gene cause sepiapterin reductase deficiency. The SPR gene provides instructions for making the sepiapterin reductase enzyme. This enzyme is involved in the production of a molecule called tetrahydrobiopterin (also known as BH4). Specifically, sepiapterin reductase is responsible for the last step in the production of tetrahydrobiopterin. Tetrahydrobiopterin helps process several building blocks of proteins (amino acids), and is involved in the production of chemicals called neurotransmitters, which transmit signals between nerve cells in the brain. SPR gene mutations disrupt the production of sepiapterin reductase. Most SPR gene mutations result in an enzyme with little or no function.
    [Show full text]